INTELLIGENT BIO SOLUTIONS INC.
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 12, 2026
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| December 31, | June 30, | |
|---|---|---|
| 2025 | 2025 | |
| (Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $740,371 | $1,019,909 |
| Accounts receivable, net | 456,657 | 594,614 |
| Subscription receivable from shareholders, net | 9,402,105 | - |
| Inventories | 590,246 | 635,215 |
| Research and development tax incentive receivable | 505,172 | 734,408 |
| Assets held for sale | - | 327,500 |
| Other current assets | 480,133 | 826,976 |
| Total current assets | 12,174,684 | 4,138,622 |
| Property and equipment, net | 321,741 | 251,325 |
| Operating lease right-of-use assets | 1,887,178 | 69,520 |
| Intangibles, net | 3,269,439 | 3,790,319 |
| Total assets | $17,653,042 | $8,249,786 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $4,261,236 | $4,534,246 |
| Current portion of operating lease liabilities | 382,518 | 84,659 |
| Current employee benefit liabilities | 470,486 | 534,990 |
| Notes payable | 13,001 | 197,146 |
| Total current liabilities | 5,127,241 | 5,351,041 |
| Employee benefit liabilities, less current portion | 106,926 | 84,921 |
| Operating lease liabilities, less current portion | 1,529,064 | - |
| Total liabilities | 6,763,231 | 5,435,962 |
| Commitments and contingencies (Note 9) | - | |
| Shareholders’ equity | ||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 1,238,446 and 1,238,434 shares issued and outstanding, respectively, as of December 31, 2025; 732,338 and 732,326 shares issued and outstanding, respectively, as of June 30, 2025* | 12,384 | 7,323 |
| Treasury stock, at cost, 12 shares as of December 31, 2025 and June 30, 2025* | (1) | (1) |
| Additional paid-in capital* | 79,540,489 | 65,849,823 |
| Accumulated deficit | (68,193,661) | (62,533,065) |
| Accumulated other comprehensive loss | (266,079) | (327,944) |
| Total consolidated Intelligent Bio Solutions Inc. equity | 11,093,132 | 2,996,136 |
| Non-controlling interest | (203,321) | (182,312) |
| Total shareholders’ equity | 10,889,811 | 2,813,824 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $17,653,042 | $8,249,786 |
| * | Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025, throughout the condensed consolidated financial statements unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.